Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2012 3
2013 2
2014 2
2015 1
2016 1
2017 1
2018 3
2019 8
2020 4
2021 4
2022 3
2023 2
2024 2
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Cortés J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, Chiu JWY, Pedrini JL, Li W, Yonemori K, Bianchini G, Loi S, Borges GS, Wang X, Bachelot T, Nakatani S, Ashfaque S, Liang Z, Egorov A, Hamilton E. Cortés J, et al. Among authors: borges gs. Nat Med. 2024 Aug;30(8):2208-2215. doi: 10.1038/s41591-024-03021-7. Epub 2024 Jun 2. Nat Med. 2024. PMID: 38825627 Free PMC article. Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
HTLV-1/2 prevalence in two Amazonian communities.
Mata EC, Bezerra RM, Proietti Júnior AA, Pamplona LK, Gomes LO, Corrêa VC, Caluff JS, Borges GS, Casseb J, Kanzaki L. Mata EC, et al. Among authors: borges gs. J Virus Erad. 2018 Jul 1;4(3):174-178. doi: 10.1016/S2055-6640(20)30261-2. J Virus Erad. 2018. PMID: 30050680 Free PMC article.
Moderate-intensity aerobic exercise training improves CD8+ tumor-infiltrating lymphocytes effector function by reducing mitochondrial loss.
Voltarelli VA, Amano MT, Tobias GC, Borges GS, Oliveira da Paixão A, Pereira MG, Saraiva Câmara NO, Caldeira W, Ribeiro AF, Otterbein LE, Negrão CE, Turner JE, Brum PC, Camargo AA. Voltarelli VA, et al. Among authors: borges gs. iScience. 2024 May 27;27(6):110121. doi: 10.1016/j.isci.2024.110121. eCollection 2024 Jun 21. iScience. 2024. PMID: 38957793 Free PMC article.
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Lorusso D, Oaknin A, Borges GS, Damian F, Ottevanger N, Van Gorp T, Paiva CE, Kroep JR, Kim YM, Kim HS, Lee JK, Denys H, Lalisang R, De Melo AC, Redondo A, Reyners AKL, Mora P, Closset C, Melief CJM, Hooftman L, Jamil S, Boersma L, Yoo SY, Seebach F, Lowy I, Fury MG, Mathias M, Colombo N. Lorusso D, et al. Among authors: borges gs. Gynecol Oncol. 2025 May;196:28-35. doi: 10.1016/j.ygyno.2025.03.019. Epub 2025 Mar 27. Gynecol Oncol. 2025. PMID: 40154184 Free article. Clinical Trial.
COVID-19 vaccine as a common good.
Borges GS, Dos Santos BF. Borges GS, et al. J Glob Health. 2021 Sep 18;11:03109. doi: 10.7189/jogh.11.03109. eCollection 2021. J Glob Health. 2021. PMID: 34671460 Free PMC article. No abstract available.
38 results